Wiregraph

Market coverage built from listed-company disclosures. Email [email protected] for any enquiries.

Copyright © 2025-2026 Wiregraph.com | Market data and charting by TradingView.com

GENMAB

GMAB.CODK0010272202NASDAQ CopenhagenDKDKK
Stock price
GENMAB
Loading chart...

Coverage

Latest articles

Genmab's experimental cancer drug shows encouraging results in endometrial cancer trial
8 Jun 2025, 20:28GMAB.CONASDAQ Copenhagen

Filings

Recent filings

FilingDate
Genmab, Capital Increase in Genmab as a Result of Employee Warrant Exercise4 Nov 2005
Genmab, Report Pursuant to Section 28a of the Danish Securities Trading Act4 Nov 2005
Genmab, Receives Patent for HuMax-HepC3 Nov 2005
InvestorService: Genmab, Data on HuMax-CD4 to be Presented at ASH1 Nov 2005
InvestorService: Genmab, Named Finalist for 2005 Scrip Awards1 Nov 2005
InvestorService: Genmab, Among Europe’s 500 Fastest Growing Companies18 Oct 2005
InvestorService: Genmab, Nominated for the 2005 World Technology Award for Biotechnology11 Oct 2005
InvestorService: Genmab, to Present HuMax-CD20 CLL Phase I/II Data at ASH
Search

Genmab A/S announced encouraging results from its Phase 1/2 RAINFOL-01 trial for rinatabart sesutecan (Rina-S), an investigational antibody-drug conjugate (ADC), in heavily pretreated patients with advanced endometrial cancer.

  • Previous
  • 1
  • 2
  • 3
  • Next
6 Oct 2005
Genmab, Bo Kruse Appointed as CFO of Genmab A/S30 Sept 2005
InvestorService: Genmab, to Present at FT Global Pharmaceutical and Biotechnology Conference30 Sept 2005
InvestorService: Genmab, to Present at UBS Global Life Sciences Conference26 Sept 2005
Genmab, Grant of Warrants21 Sept 2005
  • Previous
  • 1
  • More pages
  • 131
  • 132
  • 133
  • More pages
  • 156
  • Next
Company
GENMAB
GMAB.CONASDAQ Copenhagen
Website: Unavailable
Coverage
13
Filings
1,863